AstraZeneca PLC (NAS:AZN)

$ 67.62 0.42 (0.63%) Market Cap: 208.85 Bil Enterprise Value: 235.48 Bil PE Ratio: 32.60 PB Ratio: 5.34 GF Score: 92/100

Q3 2024 AstraZeneca PLC Earnings Call Transcript
Nov 12, 2024

$65.19 (+0.62%)

Earnings
Q2 2024 AstraZeneca PLC Earnings Presentation Transcript
Jul 25, 2024
Q1 2024 AstraZeneca PLC Earnings Call Transcript
Apr 25, 2024

$75.03 (+5.38%)

Earnings
AstraZeneca PLC Sustainability 2023 Highlights Summary Call Transcript
Mar 22, 2024
Q4 2023 AstraZeneca PLC Earnings Call Transcript
Feb 08, 2024

$63.52 (-4.55%)

Earnings
AstraZeneca PLC at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 AstraZeneca PLC Earnings Call Transcript
Nov 09, 2023

$64.09 (+0.88%)

Earnings
Q2 2023 AstraZeneca PLC Earnings Call Transcript
Jul 28, 2023

$71.33 (+4.68%)

Earnings
AstraZeneca PLC at ASCO Investor Meeting (Virtual) Transcript
Jun 05, 2023
Q1 2023 AstraZeneca PLC Earnings Call Transcript
Apr 27, 2023

$73.78 (+0.18%)

Earnings
Q4 2022 AstraZeneca PLC Earnings Call Transcript
Feb 09, 2023

$67.42 (+4.75%)

Earnings
Q4 2022 AstraZeneca PLC Earnings Presentation (Pre-Recorded) Transcript
Feb 09, 2023
Q3 2022 AstraZeneca PLC Earnings Presentation Transcript
Nov 10, 2022
Q2 2022 AstraZeneca PLC Earnings Call Transcript
Jul 29, 2022

$66.23 (-0.73%)

Earnings
AstraZeneca PLC Meet AZN management: American Society of Clinical Oncology 2022 Annual Meeting Transcript
Jun 06, 2022
Q1 2022 AstraZeneca PLC Earnings Call Transcript
Apr 29, 2022

$66.4 (-1.22%)

Earnings
AstraZeneca PLC Investor Science Conference Call: ASCO GU 2022 Transcript
Feb 23, 2022
Full Year 2021 AstraZeneca PLC Earnings Call Transcript
Feb 10, 2022

$58.6 (+2.45%)

Earnings
AstraZeneca PLC Investor science conference call: ASCO GI 2022 Transcript
Jan 24, 2022
AstraZeneca PLC at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
Nov 17, 2021
Q3 2021 AstraZeneca PLC Earnings Call Transcript
Nov 12, 2021

$58.8 (-6.55%)

Earnings
AstraZeneca PLC ESMO Investor Science Conference Call Transcript
Sep 20, 2021
Q2 2021 AstraZeneca PLC Earnings Call Transcript
Jul 29, 2021

$57.64 (+1.46%)

Earnings
AstraZeneca PLC Meet AZN Management: Oncology - 2021 ASCO Annual Meeting Transcript
Jun 07, 2021
Q1 2021 AstraZeneca PLC Earnings Call Transcript
Apr 30, 2021

$53.07 (+3.31%)

Earnings
AstraZeneca PLC BioPharmaceuticals Virtual Event - New CVRM: Emerging Pipeline Transcript
Mar 25, 2021
AstraZeneca PLC BioPharmaceuticals Virtual Event - Opening and Q&A Session Transcript
Mar 25, 2021
Full Year 2020 AstraZeneca PLC Earnings Call Transcript
Feb 11, 2021

$50.09 (+0.24%)

Earnings
AstraZeneca PLC to Acquire Alexion Pharmaceuticals Inc Call Transcript
Dec 12, 2020
Q3 2020 AstraZeneca PLC Earnings Call Transcript
Nov 05, 2020

$55.16 (+0.22%)

Earnings
AstraZeneca PLC Investor Conference Call: Farxiga's DAPA-CKD Trial at ESC 2020 Transcript
Aug 30, 2020
Q2 2020 AstraZeneca PLC Earnings Call Transcript
Jul 30, 2020

$57.89 (+2.21%)

Earnings
AstraZeneca PLC at ASCO Virtual Scientific Program Transcript
Jun 01, 2020
Q1 2020 AstraZeneca PLC Earnings Call Transcript
Apr 29, 2020

$50.72 (-0.49%)

Earnings
Silence Therapeutics PLC Collaboration With AstraZeneca and R&D Update Call Transcript
Mar 25, 2020
Full Year 2019 AstraZeneca PLC Earnings Call Transcript
Feb 14, 2020

$47.85 (-3.00%)

Earnings
AstraZeneca PLC Investor Science Conference Call - ASH 2019 Transcript
Dec 10, 2019
AstraZeneca PLC Investor Science Conference Call - ACR 2019 Transcript
Nov 13, 2019
AstraZeneca PLC Investor Science Conference Call - ASN 2019 Transcript
Nov 10, 2019
Q3 2019 AstraZeneca PLC Earnings Call Transcript
Oct 24, 2019

$47.25 (+5.73%)

Earnings
AstraZeneca PLC Investor Science Conference Call: ESMO 2019 Transcript
Sep 30, 2019
AstraZeneca PLC Investor Science Conference Call: Farxiga's DAPA-HF trial at ESC Transcript
Sep 01, 2019
Q2 2019 AstraZeneca PLC Earnings Call Transcript
Jul 25, 2019

$42.66 (+5.72%)

Earnings
AstraZeneca PLC at ASCO Annual Meeting Transcript
Jun 03, 2019
AstraZeneca PLC Annual Shareholders Meeting Transcript
Apr 26, 2019
Q1 2019 AstraZeneca PLC Earnings Call Transcript
Apr 26, 2019

$37.99 (-2.74%)

Earnings
AstraZeneca PLC to Discuss Strategic Collaboration in Oncology of Trastuzumab Deruxtecan (DS-8201) with Daiichi Sankyo Co Ltd Call Transcript
Mar 29, 2019
Daiichi Sankyo Co Ltd and AstraZeneca PLC DS-8201 Strategic Collaboration Presentation Transcript
Mar 29, 2019
Full Year 2018 AstraZeneca PLC Earnings Call Transcript
Feb 14, 2019

$39.98 (+9.29%)

Earnings

Q2 2024 AstraZeneca PLC Earnings Presentation Transcript

Jul 25, 2024 / 10:45AM GMT

Release Date Price: $78.52 (-1.49%)

Transcript

Editor

Presentation
Jul 25, 2024 / 10:45AM GMT

=====================
Corporate Participants
=====================
* Marc Dunoyer
AstraZeneca PLC - CEO of Alexion & Chief Strategy Officer
* Pascal Soriot
AstraZeneca PLC - Chief Executive Officer, Executive Director
* Sharon Barr
AstraZeneca PLC - Executive Vice President - BioPharmaceuticals R&D
* Aradhana Sarin
AstraZeneca PLC - Executive Vice President, Chief Financial Officer
* Ruud Dobber
AstraZeneca PLC - Executive Vice-President of BioPharmaceuticals Business Unit

=====================
Conference Call Participants
=====================
* Editor
* Mark Douglas Purcell
Morgan Stanley - Analyst
* James Daniel Gordon
JPMorgan Chase & Co - Analyst
* Sachin Jain
BofA Securities - Analyst
* Timothy Minton Anderson
Wolfe Research - Analyst
* Peter Welford
Jefferies LLC - Analyst

=====================

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.